Physician profile
Asia Byrd
NPI 1477321701
$3,324.42
in general payments reported to CMS, 2019-2025
27 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $998 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $381.26 | 2024-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $346.59 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Jazz Pharmaceuticals INC. | $262.24 | 2024-2025 | |
| Harmony Biosciences LLC | $260.09 | 2024-2025 | |
| Abbvie INC. | $237.24 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $215.85 | 2024-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.80 | 2024-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $146.39 | 2024-2025 | Glassia |
| Grifols USA, LLC | $137.58 | 2024-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $134.69 | 2024-2025 | Dupixent |
| Genzyme Corporation | $125.68 | 2024-2025 | |
| Inspire Medical Systems, INC. | $125.24 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $125.21 | 2024-2025 | Winrevair, Zerbaxa |
| Pfizer INC. | $76.16 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $74.85 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $71.02 | 2024-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $70.51 | 2025 | Yupelri |
| Verona Pharma, INC. | $68.80 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $53.64 | 2024-2025 | Sunosi |
| Vifor Pharma, INC. | $41.57 | 2025 | Zemaira, Veltassa |
| Amgen INC. | $39.12 | 2024 | Tezspire |
| Janssen Pharmaceuticals, INC | $38.97 | 2024 | Xarelto |
| Philips North America LLC | $35.57 | 2024 | (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $32.08 | 2024 | Yupelri |
| Baxter Healthcare | $28.47 | 2025 | Hillrom - Monarch Airway Clearance System |
| Resmed Corp | $17.90 | 2025 | |
| Pulmonx Corporation | $14.90 | 2025 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asia Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.